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Summary A quantitative analysis in vitro of events which might occur on administration of mouse
monoclonal anti-idiotypic antibody to a recipient with a B cell neoplasm has been made. The L2C leukaemic
cells of guinea pigs, which closely resemble those of human lymphoma in expression and metabolism of
immunoglobulin have been used as a model.
Exposure of neoplastic B cells to antibody results in rapid binding of approximately 420,000 molecules of
antibody per cell at saturation, and the amount consumed does not increase markedly over the next 4h of
exposure at 37°C. This is in spite of the fact that secretion of idiotypic IgM continues unaffected by the
presence of antibody, and reflects the fact that the amount of IgM secreted during this period is low
compared to the amount displayed on the cell surface. If cells undergo lysis, however, the antibody consumed
is approximately doubled: thus a recipient with an estimated tumour load of 1012 cells would require 200mg
of monoclonal anti-idiotype for binding to surface and intracellular antigen.
The effect of the soluble idiotypic IgM found in serum on the ability of antibody to bind target cells has
been examined by means of the fluorescence activated cell sorter. Access of antibody to the cells is efficiently
blocked by competing idiotypic IgM in the fluid phase, with no indication of preferential binding to cell
surface idiotype. Immunotherapeutic doses should be designed therefore to overcome this additional antigenic
load in secreting tumours, which form the majority of B cell neoplasms.
Exploration of the use of idiotypic determinants on
immunoglobulin (Ig) molecules as tumour-specific
antigens was begun for myeloma (Lynch et al.,
1972), but the use of infused anti-idiotypic antibody
to attack tumour cells holds more promise for B
lymphocytic lymphoma where the extracellular
barrier of idiotypic Ig is considerably less
(Stevenson & Stevenson, 1975). Treatment of
various animal B-cell neoplasms with such
antibodies has indicated that this approach is
feasible (Stevenson et al., 1977; Haughton et al.,
1978; Krolick et al., 1979) and there have been
some preliminary attempts to treat human disease
(Hamblin et al., 1980), with one apparent success
(Miller et al., 1982).
However, there are many factors to be taken into
account during the application of such treatment,
one of which is the level of circulating idiotypic Ig
which may block antibody attack. It has been
shown previously that many neoplastic B cell
populations secrete idiotypic IgM at low levels and
that this can accumulate in the plasma (Stevenson
et al., 1980a). Some of this material can be removed
by plasmapheresis but a question remains about the
effects of residual idiotypic IgM in the circulation,
in particular as to whether anti-idiotypic antibody
has a higher affinity for cell-bound antigen than for
fluid-phase antigen. This suggestion has been made
to account for the successful imaging of tumours
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containing carcinoembryonic antigen by specific
radiolabelled antibody, even in the face of
circulating antigen (Dykes et al., 1980).
Other factors to be considered include the
amount of anti-idiotypic antibody bound by the
target cells, and the metabolic consequenceg of
binding. There have been reports that anti-idiotypic
antibodies can switch off secretion of Ig by
neoplastic B lymphocytes (Bona & Fauci, 1980)
although this seems not to be true for plasma cells
(Milburn & Lynch, 1982): this could be important
in planning immunotherapeutic schedules.
Consumption of antibody would also occur due to
the processes of modulation and endocytosis
(Gordon & Stevenson, 1981) after which there may
be a slow re-expression of antigen (Glennie et al.,
1979). Finally, if mechanisms of tumour cell
destruction involve cell lysis, the released
intracellular Ig would consume more antibody.
These questions have been investigated in vitro
using the neoplastic B cells of the L2C leukaemia of
guinea pigs and mouse monoclonal anti-idiotypic
antibody.
Materials and methods
Leukaemic cells
The L2C leukaemia of strain 2 guinea pigs has been
described in detail (Shevach et al., 1972; Stevenson
et al., 1975); the leukaemic cells express surface
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IgMW and in culture secrete free i light chain
together with small amounts of idiotypic IgM
(Stevenson et al., 1980b). In both these
characteristics they closely resemble human B cell
neoplasms (Stevenson et al., 1980a). However, the
rate of division in vivo is much faster than most
human lymphomas having a doubling time of
approximately 20h: animals injected with 105
tumour cells on Day 0 usually die on Day 12-14
(Stevenson et al., 1977). Cells were prepared from
the peripheral blood of guinea pigs in the terminal
stage of leukaemia by gradient centrifugation on
Ficoll-Hypaque followed by washing as described
previously (Stevenson et al., 1980b).
Idiotypic IgM
In the terminal phase of the tumour, the idiotypic
IgM level in the serum reaches about 60 ,ugml- 1
and it is feasible to extract this material using a 2-
stage immunosorption procedure. This has been
described in detail (Stevenson et al., 1980b) and
involves the use of Sepharose 4B-linked sheep anti-ju
chain followed by Sepharose 4B-linked sheep anti-
idiotypic antibody: this is a polyclonal anti-idiotypic
antibody raised previously against cell surface
idiotypic determinants (Stevenson & Stevenson,
1975). The idiotypic IgM was then used to
immunize mice.
Preparation ofmonoclonal anti-idiotypic antibody
The method used was based on that of Kohler and
Milstein (1975). BALB/c mice (Avonvale, Ashley
Heath, UK) were injected with 50 jug of idiotypic
IgM in 0.2ml complete Freund's adjuvant (CFA,
Difco, Detroit, MI) distributed among four
subcutaneous sites along the back. Two weeks later,
the mice were boosted by i.v. injection of 50 jug of
the same antigen in 0.2ml PBS. After 3 days,
splenic lymphocytes from immunized mice were
fused with the NS-1 (P3-NS-l/l-Ag 4.1) mouse
myeloma line at a ratio of 2:1 by using 50%
polyethylene glycol 4000 (PEG). The fused cells
were suspended in Dulbecco's MEM containing
20% foetal calf serum, 2mM L-glutamine, 1mM
sodium pyruvate (Gibco Europe, Uxbridge,
Middlesex, UK) and 100 IU ml 1 of both penicillin
and streptomycin, to which HAT (10-4M
hypoxanthine, 4x 10-7M aminopterin and
1.6 x 10- 5 M thymidine) had been added. Cells were
distributed into wells of a 96-well microculture
plate (Gibco) at 2 x 105 spleen cells per well.
After 10-14 days colonies were clearly visible and
supernatants were screened for antibody activity.
Antibody-producing colonies were cloned into HT
medium by limiting dilution. To produce larger
amounts, 107 hybridoma cells were injected i.p. into
Pristane-primed BALB/c mice. Anti-idiotypic
antibody was purified from the ascitic fluid by
precipitation with ammonium sulphate followed by
separation on a column of Ultragel ACA 34 (LKB
Produkter, Bromma, Sweden).
Specificity ofmonoclonal antibody
A preliminary screen for antibody activity was
carried out by the enzyme-linked immunosorbent
assay (ELISA) (Engvall & Perlmann, 1972). This
was as described (Tutt et al., 1983) but in this case
antigens consisting of either idiotypic IgM or
normal guinea pig IgM were bound to the plate,
each at 20 ngml-1 in carbonate buffer. After
washing, 60jul aliquots of hybridoma supernatants
were added and bound mouse Ig detected by
exposure to horse-radish peroxidase-labelled rabbit
anti-mouse Ig (Nordic Laboratories Ltd.,
Maidenhead, Berks., UK).
Supernatants which showed strong reactivity
against idiotypic IgM and no reactivity with normal
IgM were selected and tested against other guinea
pig Igs, and then against leukaemic cells in the
presence and absence of normal guinea pig serum.
Cell reactivities were assessed by immuno-
fluorescence: cells at 2 x 107ml- (1O00pl) were
exposed to hybridoma supernatant either untreated
or previously incubated with an equal volume of
serum. After washing, bound mouse Ig was
detected by fluorescent rabbit anti-mouse Ig
(0.5mgml-1). This antibody was raised in rabbits
against mouse IgG by conventional immunization.
The IgG was prepared from the antiserum and
conjugated with fluorescein (Nairn, 1976). Antibody
activity was also tested against normal splenic
lymphocytes.
The monoclonal antibody finally selected and
expanded was shown to be of the IgG 1 subclass by
means of the ELISA technique using antisera
specific for mouse Ig classes and subclasses (Nordic
Laboratories Ltd.) as coating antibodies and
detecting bound mouse Ig as above.
Measurement ofantibody consumption
Leukaemic cells were suspended in MEM
containing 1% nonessential amino acids (Flow
Laboratories, Inc., Walkersville, MD), 2mM L-
glutamine, and lOOIUml-1 of both penicillin and
streptomycin; this was supplemented with 10%
foetal calf serum. Exposure to antibody was then
carried out under the conditions defined and cells
were removed at various times by centrifugation.
Residual antibody was then measured by the
ELISA technique using idiotypic IgM at
lOOngml-1, bound to the plates as described
above. To examine uptake of antibody by whole
cell contents, cells were lysed by suspension in
water containing a known antibody concentration,CONSUMPTION OF MONOCLONAL ANTI-IDIOTYPE BY B CELLS 409
allowed to stand for 30min at 4°C, and then
centrifuged: residual antibody was then estimated.
Secretion ofidiotypic IgM by cells
Leukaemic cells were suspended in supplemented
medium and cultured at 2 x 107mlV1 at 37°C with
gentle swirling (Stevenson et al., 1980a); samples
were taken at intervals, cooled to 0°C and cells
removed by centrifugation. The estimation of IgM
in the culture fluid was carried out by the ELISA
technique using sheep anti-Fd,u antibody (Hough et
al., 1978) at 20pgml-1 on the plate to bind IgM,
and HRP-labelled sheep anti-,u chain antibody
(4pgml-1) for detection; this antibody has been
described (Hough et al., 1978) and was coupled to
the enzyme (Sigma Chemical Co. Ltd., Poole,
Dorset, England) by glutaraldehyde (Avrameas,
1969). Standards of normal guinea pig IgM and
purified idiotypic IgM were used. In order to
examine the effect of mouse anti-idiotype on
secretion, antibody was added to the cells at 0°C
and the suspension left to stand for 30min to allow
attachment; cells were then warmed to 37°C and
swirled gently. Samples were taken at intervals for
assay of IgM production.
The effect of anti-idiotypic antibody on the
measurement of IgM in culture fluids was tested by
adding antibody at various concentrations at the
end of the incubation to culture fluids from cells
incubated alone. It was found that even the highest
concentration (5pgml-1) had no effect on the yield
of IgM in the assay, demonstrating both specificity
and a lack of any steric effect on the antigenic sites
in the constant region of the p chain.
Reactivity ofanti-idiotype with cells by
immunofluorescence
These experiments were carried out by using the
fluorescence-activated cell sorter (FACS III,
Becton-Dickinson Electronics). Cells at 2 x 107ml-1
were treated with mouse monoclonal antibody
(5,pgml-') for 30min at 4°C, washed and exposed
to fluorescent rabbit antibody against mouse IgG at
0.5mgml 1. Control samples of cells treated with
normal mouse IgG and the fluorescent antibody
gave no fluorescence. Blocking experiments were
done by incubating cells with blocking antigen and
then adding antibody, in order to mimic conditions
in vivo during infusion of antibody. Cells were
examined after removal of excess fluorescent
antibody by washing with PBS containing sodium
azide (10mM) to prevent endocytosis (Gordon &
Stevenson, 1981).
Results
Specificity ofthe monoclonal anti-idiotypic antibody
For assessment of reactivity against guinea pig
immunoglobulin antigens, the ELISA technique was
used, with the antigens attached to the microplates.
No reactivity was seen against normal pentameric
IgM, normal K or tumour-derived A light chains, or
normal IgG at concentrations of antibody
(0.5pgml-1) which gave optical densities >1.0 in
the assay using idiotypic IgM as antigen. To
investigate activity against variable region
subgroups, larger amounts (100 ngml-1) of normal
IgM were also used to attach to the microplates,
but no reactivity was detected. The A light chains
used were those obtained from the urine of guinea
pigs with the L2C leukaemia and are produced by
the tumour cells (Stevenson et al., 1980b). Lack of
reactivity indicates that the idiotypic determinants
depend on either heavy chains or heavy plus light
chain combination, as has been found for other
idiotypes (Capra, 1977).
The ability of antibody to recognize leukaemic
cells was examined by cytofluorimetry using the
FACS III: strong fluorescence was seen using
antibody at 5pgml-1 (see Figure 4 below).
Reactivity with normal guinea pig splenic or blood
lymphocytes was negligible and indistinguishable
from that of an irrelevant mouse monoclonal
antibody. Another indication of specificity is also
shown in Figure 4 where reactivity with cells is
totally unaffected by the presence of normal guinea
pig serum at a I in 4 dilution.
Consumption ofanti-idiotype by leukaemic cells
The amount of antibody consumed by leukaemic
cells in vitro at 0°C and 37°C is shown in Figure 1.
Clearly at both temperatures there is a con-
centration-dependent uptake of antibody with an
approach to a plateau at 5pgml- '. At 0°C the cells
bind 230,000 molecules of antibody per cell at
5pgml- , whereas at 37°C the figure is almost
doubled, presumably at least partly due to
metabolic processes. The kinetics of uptake of
antibody at 37°C are shown in Figure 2: binding
appears to be rapid and does not increase markedly
after the first hour. Attempts to measure the rate of
uptake at O0C showed that it was complete within
10min of exposure.
When cells were lysed in vitro by exposure to
water, antibody consumption increased by a factor
of 2.5 over consumption at 0°C, suggesting that the
intracellular compartment contains - 1.5 times the
amount of idiotypic Ig expressed at the cell surface.
A control consumption experiment using normal
guinea pig spleen cells under exactly the same410 F.K. STEVENSON et al.
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there was an almost negligible fall in antibody
activity (4%) after incubation for 4h at 37°C, and
that this occurred in the presence or absence of
normal spleen cells.
Effect ofantibody on secretion ofIgM
L2C leukaemic cells can secrete small amounts of
00C pentameric IgM in vitro (Stevenson et al., 1980b)
and the effect of the presence of anti-idiotype on
the ability of cells to secrete was examined. The
results are shown in Figure 3 and indicate no effect
of the antibody on secretion of IgM. The fact that
the cells are still secreting during exposure to
antibody at 37°C makes little difference to uptake
of antibody since the rate of secretion (30ng IgM
5 6 2x 10-7cellsh-1, or 1000 molecules of pentameric
IgM cell-lh-1) is low compared to binding by cell
.nti-idiotype surface Ig.
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Figure 2 Consumption of monoclonal anti-idiotype
by L2C leukaemic cells as a function of time of
exposure to antibody at 37°C. Cells at 2x 107ml-
were exposed to antibody at 5pgml- 1 for various
times at 37'C with swirling. Residual antibody was
measured in cell supernatants by the ELISA technique.
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Figure 3 The effect of anti-idiotype on the ability of
L2C leukaemia cells to secrete IgM. Cells at
2 x 107ml1 were cultured in the presence or absence
of anti-idiotype (5jugml-) at 37°C with swirling. Levels of IgM in cell supernatants were measured by the ELISA technique. (0) plus anti-idiotype; (0) minus anti-idiotype.
conditions as for the leukaemic cells was also
carried out. Although the immunofluorescence
experiment had indicated that there was no
reactivity of antibody with normal cells it was
necessary to examine the effect of any cellular
products on antibody activity. It was found that
Effect ofthe presence ofidiotypic IgM on binding of
antibody by cells
The ability of neoplastic B lymphocytes to secrete
idiotypic IgM in vivo can lead to an appreciable
accumulation in the plasma, dependent on tumour
load, rate of secretion and rate of catabolism. To
examine the effect of this pre-formed idiotypic IgM
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Figure 4 Reactivity of L2C leukaemic cells with anti-idiotype as shown by the fluorescence activated cell
sorter (FACS III), and the effect on it of blocking idiotypic IgM. Cells at 2 x 0I ml- were exposed to anti-
idiotype at 5pgml-' in the presence or absence of idiotypic IgM. After washing, bound mouse antibody was
detected by fluorescent rabbit anti-mouse Ig (0.5mgml-1). (a): 1. Binding of anti-idiotype by cells alone; 2.
Binding of anti-idiotype by cells to which idiotype IgM (4pgml-1 final concentration) had been added. (b): 1.
Binding of anti-idiotype by cells alone, and by cells to which normal guinea pig serum (1 in 4 dilution) had
been added; 2. binding of anti-idiotype by cells to which leukaemic serum (1 in 4 dilution) had been added.
Fluorescence gain =2.1.
on the uptake of antibody by cells, the FACS III
apparatus was used. The results are shown in
Figure 4: (a) shows the effect of adding 4pugml-'
of idiotypic IgM to 2 x 107 leukaemic cells on
subsequent binding of anti-idiotype at 5 pgml-1,
where fluorescence was reduced by - 70%. A
reduction of 50% was seen (Figure 4b) if
unfractionated leukaemic serum at a 1:4 dilution,
containing 20pgml-1 of idiotypic IgM, was used.
For both idiotypoc IgM and leukaemic serum it
was possible to dilute out the blocking activity.
Normal guinea pig serum had no effect on
antibody binding.
Discussion
Investigation of the use of anti-idiotypic antibodies
as therapeutic agents in B cell neoplasms is still at a
preliminary stage, with a number of problems re-
maining (Stevenson & Stevenson, 1983). It has been
difficult to make a systematic study of the dose
of antibody to be administered to patients, and the
only indication of sufficient antibody has been the
detection of mouse Ig in the plasma, which may be
a transient event (Miller et al., 1982). Also,
although studies have been made of some of the
metabolic sequelae of the binding of anti-idiotype
to B cells such as modulation and endocytosis
(Gordon & Stevenson, 1981), the effect of these
events on antibody consumption has not been
measured.
Using the animal model, the L2C leukaemia of
strain 2 guinea pigs, which has many features in
common with human B cell neoplasms (Stevenson
et al., 1977), and a monoclonal antibody specific
for the idiotypic determinants on the surface Ig, it
has been possible to measure uptake of antibody by
leukaemic cells under various conditions.
To simulate conditions which might occur in vivo
on administration of antibody, cells at 2 x 107ml-I
were treated with anti-idiotype at 5,ugml-'. Results
indicate that the cells rapidly bind antibody
approaching saturation at 4.2 x 105 molecules per
cell. Thus for a patient with a tumour load of 1012
cells, 105mg of monoclonal antibody would be
required for such binding, and if the volume of
plasma plus extracellular fluid is taken as 151 the
antibody would be presented to cells at a
concentration of 7pgml-'. The observation that
consumption appears to be quite slow after the first
hour means that there is little point in giving more
antibody during at least the next 4 hours.
The fate of tumour cells which have bound
antibody is not yet clear, with some evidence
emerging that antibody-dependent cellular
cytotoxicity may be a mechanism which is activated
(Herlyn & Koprowski, 1982). The anti-idiotype is
of the IgG 1 subclass like the majority of mouse
monoclonal antibodies produced; it has been
reported recently that this subclass is able to
mediate cellular cytotoxicity (Ralph & Nakoinz,
1983). If cells do undergo lysis, intracellular
contents may be released and if idiotypic Ig is
present, more antibody will be consumed. In the
L2C model the amount of antibody consumed by
lysed cells is more than twice that for viable cells.
There have been a number of studies on the
effect of anti-Ig reagents on secretion of Ig by B
lymphocytes, although such experiments are
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complicated by the fact that antibody will react
with secreted Ig to form immune complexes which
are difficult to measure. Results reported are
diverse with antibody inhibiting secretion in some
systems and not in others. In the well-studied
mouse myeloma, MOPC-315, it has been shown
that anti-idiotypic antibody does not inhibit
secretion of the idiotypic IgA (Milburn & Lynch,
1982). However, in a study of human chronic
lymphocytic leukaemia with cells secreting an IgM
paraprotein, sheep anti-idiotypic antibody did
inhibit secretion (Bona & Fauci, 1980). The guinea
pig leukaemia is convenient to study since the
monoclonal anti-idiotype does not affect the
subsequent assay of IgM, and using this system no
inhibition of secretion was detected over the time
period studied.
One of the major problems in the use of anti-
idiotypic antibody therapy is that most neoplastic B
cell populations secrete small amounts of idiotypic
Ig and this can accumulate in the plasma. This
generalization appears to apply to the broad
spectrum of human B cell neoplasms including
chronic lymphocytic leukaemia and follicular
lymphoma (Stevenson et al., 1982). Plasmapheresis
can lower the plasma concentration by some 50-
60% (Stevenson et al., 1980a). Residual idiotypic Ig
in the plasma would be expected to compete for
administered antibody and the results of this study
demonstrate that this can occur: idiotypic IgM at
4yugml-' reduced fluorescence due to antibody at
5pgml-' by 70%. The report that tumour
localization of radiolabelled polyclonal goat
antibody to carcinoembryonic antigen occurs in the
presence of excess circulating antigen is difficult to
account for if the tumour-associated and circulating
antigens are antigenically identical and it has been
suggested that differences could exist (Primus et al.,
1980). The presence of idiotypic Ig in the plasma
will require an increase in the dose of antibody of
an amount at least equivalent to the mass of Ig in
the plasma. Normal pentameric IgM is -75%
localized to the vascular compartment, but it is not
clear if this will be the case for IgM arising from
tumour cells of abnormal distribution.
It is suggested that the application of these
simple experiments to a sample of a patient's cells
in vitro would allow prediction of some of the
requirements for a possible attack by anti-idiotype
on B cell neoplasms. Consumption due to specific
antibody function must be superimposed upon
those factors attenuating the concentration of any
infused xenogenic Ig: dispersion through the
extracellular fluids, uptake by weakly cross-reacting
molecules, nonspecific catabolic destruction, and -
when an anti-Ig response finally becomes evident -
immunological removal.
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